Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03238248 · ClinicalTrials.gov registry record · Phase 2
Pevonedistat and Azacitidine in MDS or MDS/MPN Patients Who Fail Primary Therapy With DNA Methyl Transferase Inhibitors
A Phase 2 study, sponsored by Vanderbilt-Ingram Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 71
- Enrollment target
NCT03238248 is a Phase 2 study that has completed, run by Vanderbilt-Ingram Cancer Center. The registered enrollment target is 71 participants.
The verdict
NCT03238248, a Phase 2 study, has completed, sponsored by Vanderbilt-Ingram Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 71 participants
- Enrollment target
Study Summary
This study will evaluate the treatment combination of pevonedistat and azacitidine in the setting of DNA methyltransferase inhibitor(s) failure in patients with relapsed/refractory myelodysplastic syndrome or myelodysplastic syndrome/myeloproliferative neoplasm.
Interventions
- DRUG Azacitidine Subcutaneous Injection or Intravenous Infusion
- DRUG Pevonedistat Infusion
- PROCEDURE Bone Marrow Biopsy & Aspirate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 71 participants |
| Start Date | 2017-08-07 |
| Est. Completion | 2023-11-27 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03238248
The ClinicalTrials.gov registry entry for NCT03238248 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 71 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vanderbilt-Ingram Cancer Center, which has 189 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Azacitidine Subcutaneous Injection or Intravenous Infusion is the first listed.
NCT03238248 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03238248 about?
NCT03238248 is a clinical study titled "Pevonedistat and Azacitidine in MDS or MDS/MPN Patients Who Fail Primary Therapy With DNA Methyl Transferase Inhibitors". This study will evaluate the treatment combination of pevonedistat and azacitidine in the setting of DNA methyltransferase inhibitor(s) failure in patients with relapsed/refractory myelodysplastic syndrome or myelodysplastic syndrome/myeloproliferative neoplasm.
What is the current status of trial NCT03238248?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 71 participants. The study started on 2017-08-07. Estimated completion is 2023-11-27.
What interventions are being tested in trial NCT03238248?
The interventions under investigation include: Azacitidine Subcutaneous Injection or Intravenous Infusion (DRUG), Pevonedistat Infusion (DRUG), Bone Marrow Biopsy & Aspirate (PROCEDURE).
Who is sponsoring clinical trial NCT03238248?
This trial is sponsored by Vanderbilt-Ingram Cancer Center, which has 189 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.